21 Jul 2022 15:30
Circassia Group PLC
("Circassia" or the "Company")
Change of Auditor
Circassia Group PLC, (AIM: CIR), a company engaged in the design, development and commercialisation of medical devices for asthma diagnosis and management, announces that it has changed its auditor for the financial year ending 31 December 2022 ("FY 22").
The Company has appointed RSM UK Audit LLP as auditor for FY 22.
PwC LLP, the Company's outgoing auditor, has confirmed to the Company that, in accordance with section 519 of the Companies Act 2006, there are no circumstances in connection with its resignation which it considers need to be brought to the attention of the Company's members or creditors.
Any proposal to re-appoint RSM UK Audit LLP as independent auditor for the financial year ending 31 December 2023 will be subject to approval by the Company's shareholders at the Company's 2023 annual general meeting.
Contacts
Circassia
Ian Johnson, Executive Chairman Tel: +44 (0) 1865 405 560
Michael Roller, Chief Financial Officer
Singer Capital Markets (Nominated Adviser and Broker)
Aubrey Powell/ Jen Boorer Tel: +44 (0) 20 7496 3000
About Circassia
Our ambition is to improve the quality of life of millions of people suffering from asthma. The company is engaged in the design, development and commercialisation of medical devices for the diagnosis and management of asthma. Today our device, NIOX VERO, is used by healthcare professionals and leading research organisations. We passionately believe in empowering everyone to manage their health at home and are developing NIOX for home use to meet this need. At present, Circassia provides products and services in around 50 countries. For more information please visit www.circassia.com.